ALSO NOTED: Dr. Reddy's takes a gamble on biogenerics; Coley receives $5M from Dynavax; and much more...

> Brian Orelli of the Motley Fool profiles a risky move by generic drugmaker Dr. Reddy's Laboratories. Article

> In New Jersey, the biotech industry is booming. Article

> Coley will receive at least $5 million from Dynavax Technologies for the nonexclusive marketing rights to commercialize Coley's hepatitis B vaccine Heplisav. The therapy is in late-stage trials. Release

> Keryx Biopharmaceuticals presented positive data on the clinical activity of KRX-0401 (perifosine) in patients with advanced multiple myeloma and Waldenstrom's macroglobulinemia. Release

> An expert panel has delayed a decision on endorsing FluMist for children under 5, a move that will likely close that market to MedImmune for the upcoming flu season. Report

> The European Commission has granted Merck KGaA marketing approval for its fertility drug Pergoveris. Report

> France's NicOx has begun its third pivotal Phase III clinical trial for naproxcinod in patients with osteoarthritis of the hip. Release

And Finally... Research shows that exercise creates new brain cells. Release

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.